A high-fat diet and multiple administration of carbon tetrachloride induces liver injury and pathological features associated with non-alcoholic steatohepatitis in mice

Clinical and Experimental Pharmacology and Physiology

Volumn 40, Issue 7, 2013, Pages 422-430

  Kubota, Norihiro ^a   Kado, Shoichi ^a   Kano, Mitsuyoshi ^a   Masuoka, Norie ^a   Nagata, Yuriko ^a   Kobayashi, Toshihide ^a   Miyazaki, Kouji ^a   Ishikawa, Fumiyasu ^a  

^a YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

Author keywords

Apoptosis; Carbon tetrachloride; Fat accumulation; Fibrosis; Inflammation; Non alcoholic fatty liver; Oxidative stress

Indexed keywords

ALANINE AMINOTRANSFERASE; CARBON TETRACHLORIDE; GLUTATHIONE; GLUTATHIONE DISULFIDE; HYDROXYPROLINE; MESSENGER RNA; MITOCHONDRIAL DNA; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ENZYME ACTIVITY; FATTY LIVER; GENE DOSAGE; HISTOPATHOLOGY; INFLAMMATION; LIPID DIET; LIVER FIBROSIS; LIVER INJURY; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS;

ALANINE TRANSAMINASE; ANIMALS; APOPTOSIS; CARBON TETRACHLORIDE; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DNA COPY NUMBER VARIATIONS; DNA, MITOCHONDRIAL; FATTY LIVER; FIBROSIS; GLUTATHIONE; GLUTATHIONE DISULFIDE; INFLAMMATION; LIVER; LIVER DISEASES; MALE; MICE; MICE, INBRED C57BL; OBESITY; OXIDATIVE STRESS; RNA, MESSENGER; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879514564     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12102     Document Type: Article

References (27)

1. Neuschwander Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-19.
2. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39: 188-96.
3. Hyogo H, Tazuma S, Arihiro K, et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008; 57: 1711-8.
4. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: A pilot study. Aliment. Pharmacol. Ther. 2001; 15: 1667-72.
5. Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study. Hepatology 1996; 23: 1464-7.
6. Hebbard L, George J. Animal models of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 2011; 8: 35-44.
7. Svegliati Baroni G, Candelaresi C, Saccomanno S, et al. A model of insulin resistance and nonalcoholic steatohepatitis in rats: Role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am. J. Pathol. 2006; 169: 846-60.
8. Sahai A, Malladi P, Pan X, et al. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: Role of short-form leptin receptors and osteopontin. Am. J. Physiol. Gastrointest. Liver Physiol. 2004; 287: G1035-43.
9. Phung N, Pera N, Farrell G, Leclercq I, Hou JY, George J. Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis. Int. J. Mol. Med. 2009; 24: 171-80.
10. Fan JG, Qiao L. Commonly used animal models of non-alcoholic steatohepatitis. Hepatobil. Pancreat. Dis. Int. 2009; 8: 233-40.
11. Larter CZ, Yeh MM. Animal models of NASH. Getting both pathology and metabolic context right. J. Gastroenterol. Hepatol. 2008; 23: 1635-48.
12. Day CP, James OF. Steatohepatitis. A tale of two 'hits'? Gastroenterology 1998; 114: 842-5.
13. 1A-deficient mice show less severe progression of liver fibrosis induced by CCl(4). Biochem. Biophys. Res. Commun. 2003; 308: 177-83.
14. Bergman I, Loxley R. The determination of hydroxyproline in urine hydrolysates. Clin. Chim. Acta 1970; 27: 347-9.
15. Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: Carbon tetrachloride as a toxicological model. Crit. Rev. Toxicol. 2003; 33: 105-36.
16. Wei Y, Rector RS, Thyfault JP, Ibdah JA. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J. Gastroenterol. 2008; 14: 193-9.
17. Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 2006; 87: 1-16.
18. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
19. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J. Clin. Invest. 2000; 105: 1067-75.
20. Deng QG, She H, Cheng JH, et al. Steatohepatitis induced by intragastric overfeeding in mice. Hepatology 2005; 42: 905-14.
21. Ito M, Suzuki J, Tsujioka S, et al. Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to high-fat diet. Hepatol. Res. 2007; 37: 50-7.
22. Park CM, Cha YS, Youn HJ, Cho CW, Song YS. Amelioration of oxidative stress by dandelion extract through CYP2E1 suppression against acute liver injury induced by carbon tetrachloride in Sprague-Dawley rats. Phytother. Res. 2010; 24: 1347-53.
23. Campo GM, Squadrito F, Ceccarelli S, et al. Reduction of carbon tetrachloride-induced rat liver injury by IRFI 042, a novel dual vitamin E-like antioxidant. Free Radic. Res. 2001; 34: 379-93.
24. Madan K, Bhardwaj P, Thareja S, Gupta SD, Saraya A. Oxidant stress and antioxidant status among patients with nonalcoholic fatty liver disease (NAFLD). J. Clin. Gastroenterol. 2006; 40: 930-5.
25. Alkhouri N, Carter Kent C, Feldstein AE. Apoptosis in nonalcoholic fatty liver disease: Diagnostic and therapeutic implications. Expert Rev. Gastroenterol. Hepatol. 2011; 5: 201-12.
26. Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125: 437-43.
27. Bataller R, Brenner DA. Liver fibrosis. J. Clin. Invest. 2005; 115: 209-18.